NSAID-induced ulcers

  • Jay L. Goldstein
  • Russell D. Brown

Opinion statement

Nonselective nonsteroidal antiinflammatory drugs (NSAIDs) are used chronically by approximately 13 million to 15 million Americans annually for the treatment of painful and inflammatory conditions. While all these agents are quite effective in reducing inflammation and pain, they are also associated with UGI symptoms and mucosal injury. These include abdominal pain/dyspepsia in the absence of ulcer disease; symptomatic and asymptomatic gastric and duodenal ulcers; and clinically significant upper GI events such as bleeding, gastric outlet obstruction, and perforation.

The clinically relevant treatments related to NSAID-associated symptoms and mucosal injury fall into three major categories: symptomatic treatment of dyspepsia while using NSAIDs; treatment of acute endoscopically proven ulcers and ulcer complications in those using these medications; and prevention (prophylaxis) of ulcer and ulcer complications in patients at high risk for ulcer complications.

The new COX-2 selective inhibitors are likely to be associated with different short- and long-term safety profiles as compared to traditional NSAIDs; the literature and post-marketing data regarding these agents (celecoxib, rofecoxib) are evolving. As such, this article primarily focuses on the approach to patients using traditional, nonselective, nonsteroidal agents.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Fries JF: NSAID gastropathy: epidemiology. J Musculoskel Med 1991, 8:21–28.Google Scholar
  2. 2.
    Roth SH: NSAID gastropathy: a new understanding. Arch Intern Med 1996, 156:1623–1628.PubMedCrossRefGoogle Scholar
  3. 3.
    Wilcox CM, Shalek KA, Cotsonis G: Striking prevalence of over-the-counter nonsteroidal antiinflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med 1994, 154:42–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature (New Biology) 1971, 231:232–235.Google Scholar
  5. 5.
    Davies P, Bailey PJ, Goldenberg MM, et al.: The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol 1984, 2:335–357.PubMedCrossRefGoogle Scholar
  6. 6.
    Needleman P, Turk J, Jakschik BA, et al.: Arachidonic acid metabolism. Annu Rev Biochem 1986, 55:69–102.PubMedCrossRefGoogle Scholar
  7. 7.
    Smith WL, DeWitt DL: Prostaglandin endoperoxide H synthases -1 and -2. Adv Immunol 1996, 62:167–215.PubMedCrossRefGoogle Scholar
  8. 8.
    Xie W, Chipman JG, Robertson DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991, 88:2692–2696.PubMedCrossRefGoogle Scholar
  9. 9.
    Kujubu DA, Fletcher BS, Varnum BC, et al.: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991, 266:12866–12872.PubMedGoogle Scholar
  10. 10.
    O’Banion MK, Sadowski HB, Winn V et al.: A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991, 266:23261–23267.PubMedGoogle Scholar
  11. 11.
    Gierse JK, Hauser SD, Creely DP, et al.: Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J 1995, 305:479–484.PubMedGoogle Scholar
  12. 12.
    Laneuville O, Breuer DK, DeWitt DL, et al.: Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal antiinflammatory drugs. J Pharmacol Exp Ther 1994, 271:927–934.PubMedGoogle Scholar
  13. 13.
    Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: a metaanalysis. Ann Intern Med 1991, 115:787–796.PubMedGoogle Scholar
  14. 14.
    Garcia Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal antiinflammatory drugs. Lancet 1994, 343:769–772.PubMedCrossRefGoogle Scholar
  15. 15.
    Langman MJS, Weil J, Wainwright P, et al.: Risks of bleeding peptic ulcer associated with individual nonsteroidal antiinflammatory drugs. Lancet 1994, 343:1075–1078.PubMedCrossRefGoogle Scholar
  16. 16.
    Singh G, Ramey DR: NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism and Aging Medical Information System. J Rheumatol 1998, 25(51):8–16.Google Scholar
  17. 17.
    Silverstein FE, Graham DY, Senior JR, et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241–249.PubMedGoogle Scholar
  18. 18.
    MacDonald TM, Morant SV, Robinson GC, et al.: Association of upper gastrointestinal toxicity of nonsteroidal antiinflammatory drugs with continued exposure: cohort study. BMJ1997, 315:1333–1337.PubMedGoogle Scholar
  19. 19.
    Wolfe MM, Lichtenstein DR, G Singh: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888–1898. This is an outstanding review and very well worth the time to fully understand the scope of NSAID-associated GI toxicity.PubMedCrossRefGoogle Scholar
  20. 20.
    Singh G, Ramey DR, Morfeld D, et al.: Gastrointestinal tract complications of nonsteroidal antiinflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996; 156:1530–1536.PubMedCrossRefGoogle Scholar
  21. 21.
    Armstrong CP, Blower AL: Nonsteroidal antiinflammatory drugs and life threatening complications of peptic ulceration. Gut 1987, 28:527–532.PubMedGoogle Scholar
  22. 22.
    Larkai EN, Smith JL, Lidsky MD, et al.: Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989, 11:158–162.PubMedCrossRefGoogle Scholar
  23. 23.
    Larkai EN, Smith JL, Lidsky MD, et al.: Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal antiinflammatory drug use. Am J Gastroenterol 1987, 82:1153–1158.PubMedGoogle Scholar
  24. 24.
    Geis GS, Stead H, Wallemark CB, et al.: Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac-associated lesions. J Rheumatol 1991, 18(28):11–14.Google Scholar
  25. 25.
    Gutthann SP, Garcia Rodriguez LA, Raiford DS: Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997, 8:18–24.PubMedCrossRefGoogle Scholar
  26. 26.
    Fries JF: NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991, 18(28):6–10.Google Scholar
  27. 27.
    Singh G, Ramey DR, Triadafilopoulus G, et al.: GI SCORE: a simple self-assessment instrument to quantify the risk of serious NSAID-related GI complications in RA and OA. Arthritis Rheum 1998, 41:S75.Google Scholar
  28. 28.
    Goldstein JL, Lefkowith JB: Public misunderstanding of nonsteroidal antiinflammatory drugs (NSAID)-mediated gastrointestinal (GI) complications toxicity: A serious potential health threat. Gastroenterology 1998, 114:G0555.Google Scholar
  29. 29.
    Singh G, Ramey DR, Triadafilopoulus G: Epidemiology of NSAID-induced GI complications. J Rheumatol 1999, 26(26):18–24.Google Scholar
  30. 30.
    Hochberg MC, Altman RD, Brandt KD, et al.: Guidelines for the medical management of osteoarthritis. Arth Rheum 1995, 38(11):1535–1540.CrossRefGoogle Scholar
  31. 31.
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996, 39(5):713–722.CrossRefGoogle Scholar
  32. 32.
    Laine L, Marin-Sorensen M, Weinstein WM: Nonsteroidal antiinflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 1992, 87:1398–1402.PubMedGoogle Scholar
  33. 33.
    Laine L, Cominelli F, Sloan R, et al.: Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther 1995, 9:127–135.PubMedCrossRefGoogle Scholar
  34. 34.
    Kim JG, Graham DY: Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol 1994, 89:203–207.PubMedGoogle Scholar
  35. 35.
    Gubbins GP, Schubert TT, Attanasio F, et al.: Helicobacter pylori seroprevalence in patients with rheumatoid arthritis: effect of nonsteroidal antiinflammatory drugs and gold compounds. Am J Med 1992, 93:412–418.PubMedCrossRefGoogle Scholar
  36. 36.
    Graham DY, Lidsky MD, Cox AM, et al.: Long-term nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection. Gastroenterology 1991, 100:1653–1657.PubMedGoogle Scholar
  37. 37.
    Konturek JW, Fuchs W, Elbret J, et al.: The prevalence of Helicobacter pylori (Hp) infection in long-term users of nonsteroidal anti-inflammatory drugs. Gastroenterology 1998, 114:G0762.CrossRefGoogle Scholar
  38. 38.
    Graham DY: Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996, 10:2080–2086.Google Scholar
  39. 39.
    Chan FKL, Sung JY, Chung SCS, et al.: Randomized trial of eradication of Helicobacter pylori before nonsteroidal antiinflammatory drug therapy to prevent peptic ulcers. Lancet 1997, 350:975–979.PubMedCrossRefGoogle Scholar
  40. 40.
    Lai KC, Lam SK, Hui WM, et al.: Can eradication of Helicobacter pylori prevent future development of peptic ulcers in patients receiving long-term continuous nonsteroidal antiinflammatory drugs? Gastroenterology 1998, 114:A192.Google Scholar
  41. 41.
    Hawkey CJ, Tullassay Z, Szcepanski L, et al.: Failure of Helicobacter pylori eradication to influence site-specific relapse in high risk NSAID users: Results of a large six month double blind randomized controlled clinical trial. Gastroenterology 1998, 114:G0594.Google Scholar
  42. 42.
    Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: Ranitidine versus omeprazole for NSAID-associated treatment(ASTRONAUT) study group. N Engl J Med 1998, 338:727–734.PubMedCrossRefGoogle Scholar
  43. 43.
    Campbell DR, Shah N, Winston B, et al.: Effect of H. pylori status on healing of gastric ulcer in patients continuing to take NSAIDs and treated with lansoprazole or ranitidine. Gastroenterology 1998, 114:G0339.Google Scholar
  44. 44.
    Agrawal NM, Roth S, Graham DY, et al.: Misoprostol compared with sucralfate in the prevention of nonsteroidal antiinflammatory drug-induced gastric ulcer. Ann Intern Med 1991, 115:195–200.PubMedGoogle Scholar
  45. 45.
    Raskin JB, White RH, Jackson JE, et al.: Misoprostol dosage in the prevention of nonsteroidal antiinflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995, 123(5):344–350.PubMedGoogle Scholar
  46. 46.
    De Melo Gomes JA: The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis: an assessment of the upper gastrointestinal tract by endoscopy. Scand J Rheumatol 1992, S26:23–31.CrossRefGoogle Scholar
  47. 47.
    Yeomans ND, Tulassay Z, Juhasz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998, 338:719–726.PubMedCrossRefGoogle Scholar
  48. 48.
    Agrawal N, Farmington CT, Safdi M, et al.: Effectiveness of lansoprazole in the healing of NSAID-indued gastric ulcer in patients continuing to take NSAIDs. Gastroenterology 1998, 114:G0213.CrossRefGoogle Scholar
  49. 49.
    Lancaster-Smith MJ, Jaderberg ME, Jackson DA: Ranitidine in the treatment of nonsteroidal antiinflammatory drug associated gastric and duodenal ulcers. Gut 1991, 32:252–255.PubMedGoogle Scholar
  50. 50.
    Hudson N, Taha AS, Russel RI, et al.: Famotidine for healing and maintenance in nonsteroidal antiinflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997, 112:1817–1822.PubMedCrossRefGoogle Scholar
  51. 51.
    Lipsky PE: Proceedings of a symposium: COX-2 specific inhibitors: basic science and clinical implications. Am J Med 1999, 106:5B. This is a special review of COX-2 technology and is highly recommended. Several articles are included in this supplement and will serve as an excellent, timely and updated reference.CrossRefGoogle Scholar
  52. 52.
    Hawkey CJ: COX-2 inhibitors. Lancet 1999, 353: 307–314. This review describes the concepts related to COX-2 technology and is very well written.PubMedCrossRefGoogle Scholar
  53. 53.
    Geis GS, Stead H, Morant S, et al.: Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998, 41(9):1699.Google Scholar
  54. 54.
    Geis GS, Hubbard R, Callison D, et al.: Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998, 41(9):1990.Google Scholar
  55. 55.
    Laine L, Hawkey C, Harper S, et al.: Effect of the COX-2 specific inhibitor (C-2SI) rofecoxib on ulcer formation: a double-blind comparison with ibuprofen and placebo. Gastroenterology 1999, 116(2):G0996.Google Scholar
  56. 56.
    Burke TA, Goldstein JL, Pettitt AD, et al.: Increased upper gastrointestinal (UGI) distress among arthritis patients treated with NSAIDs as compared to celecoxib and placebo. Val Health 1999, 2(3):154–155.Google Scholar
  57. 57.
    Goldstein JL, Agrawal N, Silverstein F, et al.: Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OA) and rheumatoid arthritis (RA) patients as compared to NSAIDs. Gastroenterology 1999, 116(4):A174.Google Scholar
  58. 58.
    Langman M, Jensen D, Harper S, et al.: Lower incidence of clinically evident upper-GI perforations, ulcers and bleeds in patients treated with rofecoxib vs. nonspecific cyclooxygenase inhibitors. Gastroenterology 1999, 116(4):G1008.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Jay L. Goldstein
    • 1
  • Russell D. Brown
    • 1
  1. 1.Section of Digestive and Liver DiseasesUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations